Search Results - "Clos, A."

Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice by Lasagna-Reeves, C., Gonzalez-Romero, D., Barria, M.A., Olmedo, I., Clos, A., Sadagopa Ramanujam, V.M., Urayama, A., Vergara, L., Kogan, M.J., Soto, C.

“…Gold nanoparticles (GNPs) offer a great promise in biomedicine. Currently, there is no data available regarding the accumulation of nanoparticles in vivo after…”
Get full text

Viral Upper Respiratory Tract Infection and Otitis Media Complication in Young Children by Chonmaitree, Tasnee, Revai, Krystal, Grady, James J., Clos, Audra, Patel, Janak A., Nair, Sangeeta, Fan, Jiang, Henrickson, Kelly J.

“…Background. The common cold or upper respiratory infection (URI) is highly prevalent among young children and often results in otitis media (OM). The incidence…”
Get full text

Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis by Clos, A.L., Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Jackson, G.R., Kelly, B., Beachkofsky, T.M., Kayed, R.

“…Summary Background  Primary cutaneous nodular amyloidosis (PCNA) is thought to be a plasma cell dyscrasia. The amyloid deposits are found in the dermis and…”
Get full text

Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV) by Maier, M, Feucht, N, Haas, K, Fiore, B, Winkler von Mohrenfels, C, Clos, A, Lohmann, C

“…Systemic anti-VEGF therapy with bevacizumab was effective in neovascular AMD in the SANA study. Intravitreal bevacizumab has the advantage that a high…”
Get more information

Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for occult and classic CNV in AMD by Maier, M, Haas, K, Feucht, N, Fiore, B, Winkler von Mohrenfels, C, Clos, A, Lohmann, C

“…The aim of this study is to discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab (1.25 mg) in occult and…”
Get more information

P609 Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapy by Cañete, F, Lobatón, T, Cabré, E, Mañosa, M, Teniente, A, Clos, A, Torres, P, Valldosera, G, Martínez-Cáceres, E, Domènech, E

“…Abstract Background It has been suggested that infliximab (IFX) trough levels (ITL) may be useful in different clinical settings in inflammatory bowel disease…”
Get full text

P835 Correlation between microbial markers and faecal calprotectin in IBD patients by Amoedo Cibeira, J, Ramió-Pujol, S, Serra-Pagès, M, Bahí, A, Puig-Amiel, C, Oliver, L, Gilabert, P, Clos, A, Mañosa, M, Cañete, F, Miquel-Cusachs, J O, Torrealba, L, Busquets, D, Sàbat, M, Domènech, E, Guardiola, J, Garcia-Gil, J, Aldeguer, X

“…Abstract Background Crohn disease (CD) and Ulcerative colitis (UC) are characterised by episodes of exacerbations and remissions. Monitoring disease activity…”
Get full text

P740 Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experience by González Muñoza, C, Mesonero, F, Bargalló, A, Clos, A, Aràjol, C, Gordillo, J, López- San Román, A, Guardiola, J, Navarro-Llavat, M, Bertoletti, F, Fernández, C, Domènech, E, Garcia-Planella, E

“…Abstract Background Vedolizumab (VDZ) is a monoclonal antibody that blocks integrin α4β7 preventing the migration of lymphocytes to the intestinal wall,…”
Get full text

P251 RAID Dx: the first test based on faecal microbiota to differentiate irritable bowel syndrome from inflammatory bowel diseases by Amoedo, J, Ramió-Pujol, S, Bahí, A, Puig-Amiel, C, Oliver, L, Torrealba, L, Ibáñez-Sanz, G, Clos, A, Mañosa, M, Cañete, F, Marín, I, Torres, P, Gilabert, P, Miquel-Cusachs, J O, Busquets, D, Serra-Pagès, M, Sàbat, M, Serra, J, Domènech, E, Guardiola, J, Mearin, F, Garcia-Gil, L J, Aldeguer, X

“…Abstract Background The irritable bowel syndrome (IBS) is a functional disorder affecting up to 20% of world population. So far, there is not a specific…”
Get full text

P162 RAID-Monitor: a new non-invasive method to determine endoscopic activity in inflammatory bowel diseases by Amoedo, J, Ramió-Pujol, S, Bahí, A, Puig-Amiel, C, Oliver, L, Gilabert, P, Clos, A, Mañosa, M, Cañete, F, Torrealba, L, Miquel-Cusachs, J O, Busquets, D, Serra-Pagès, M, Sàbat, M, Domènech, E, Guardiola, J, Garcia-Gil, L J, Aldeguer, X

“…Abstract Background Crohn’s disease (CD) and ulcerative colitis (UC) are characterised by episodes of exacerbations and remissions. Monitoring disease activity…”
Get full text

P213 RAID-IBS Diagnosis: A new non-invasive method to support Irritable Bowel Syndrome diagnosis by Amoedo, J, Ramió-Pujol, S, Bahí, A, Oliver, L, Torrealba, L, Clos, A, Cañete, F, Mañosa, M, Ibáñez-Sanz, G, Gilabert, P, Serra-Pagès, M, Miquel-Cusachs, J O, Busquets, D, Sàbat, M, Domènech, E, Guardiola, J, Mearin, F, Garcia-Gil, L J, Aldeguer, X

“…Abstract Background Irritable Bowel Syndrome (IBS) is a functional disorder affecting up to 10% of world population. Diagnostics is mainly based on clinical…”
Get full text

P663 Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry by Cañete, F, Mañosa, M, Casanova, M J, González-Sueyro, R C, Barrio, J, Bermejo, F, Nos, P, Iglesias, E, Garcia-Planella, E, Perez-Calle, J L, Ramos, L, De Francisco, R, Rivero, M, Montserrat, A, Navarro, P, Taxonera, C, Hinojosa, J, Núñez, A, Navarro-Llavat, M, Ramírez-de la Piscina, P, Fernández, L, Almela, P, Ríos, R, Clos, A, Cabré, E, Domènech, E

“…Abstract Background Anti-TNF and thiopurines are the only drugs that demonstrated efficacy in preventing postoperative recurrence (POR) in Crohn’s disease…”
Get full text

P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry by Guasch, M, Clos, A, Ordás, I, García-Sánchez, V, Gisbert, J P, Taxonera, C, Vera, I, Mínguez, M, Guardiola, J, López-Sanromán, A, Rivero-Tirado, M, Nos, P, Gomollón, F, Carbajo, A Y, de Francisco, R, Martín-Arranz, M D, Garcia-Planella, E, García-López, S, de Castro, L, Calvet, X, Camargo, R, Esteve, M, Sicilia, B, Andreu, M, Macho, A, Piqueras, M, Bermejo, F, Gutiérrez, A, Busquets, D, Martínez-Montiel, P, Hinojosa, J, Pérez-Calle, J L, Bujanda, L, Rodríguez-Pérez, A, Lorente, R, Jiménez, N, Navarro-Llavat, M, Cabriada, J L, Camo, P, Van Domselaar, M, Rodríguez-González, E, Rodríguez-Gutiérrez, C, Huguet, J M, Lucendo, A J, Argüelles, F, Almela, P, Merino, O, Calafat, M, Ogueta, M, Charro, M, Llaó, J, Muñoz, C, Ramos, L, Abad, Á, Roncero, Ó, Barreiro-de-Acosta, M, Sesé, E, Mañosa, M, Domènech, E

“…Abstract Background It has been suggested that biological therapies might change the natural history of IBD, avoiding surgery in a proportion of patients…”
Get full text

Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease by Rodríguez‐Lago, Iago, Castro‐Poceiro, Jesús, Fernández‐Clotet, Agnès, Mesonero, Francisco, López‐Sanromán, Antonio, López‐García, Alicia, Márquez, Lucía, Clos‐Parals, Ariadna, Cañete, Fiorella, Vicuña, Miren, Nantes, Óscar, Merino, Olga, Matallana, Virginia, Gordillo, Jordi, Elorza, Ainara, Vicente, Raquel, Casanova, María José, Ferreiro‐Iglesias, Rocío, Pérez‐Galindo, Pablo, Benítez, José Manuel, Taxonera, Carlos, García, María José, Martín, Eduardo, Aguirre, Urko, Gisbert, Javier P., Rodríguez‐Lago, I., Elorza, A., Castro‐Poceiro, J., Fernández‐Clotet, A., Mesonero, F., López‐Sanromán, A., López‐García, A., Márquez, L., Clos‐Parals, A., Cañete, F., Vicuña, M., Nantes, O., Merino, O., Matallana, V., Gordillo, J., Vicente, R., Casanova, M. J., Gisbert, J. P., Ferreiro‐Iglesias, R., Pérez‐Galindo, P., Manuel Benítez, J., Taxonera, C., García, M. J., Martín, E., Aguirre, U., Calafat, M., Muñoz, F., Miquel‐Cusachs, J. O., Sáinz, E.

“…Summary Background Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but…”
Get full text

P223 Efficacy and safety of tacrolimus in Crohn’s disease: a nationwide, multi-centric study from GETECCU by Rodriguez-Lago, I, Castro-Poceiro, J, Fernández-Clotet, A, Mesonero, F, López-Sanromán, A, López-García, A, Márquez, L, Clos-Parals, A, Cañete, F, Vicuña, M, Nantes, Ó, Merino, O, Matallana Royo, V, Gordillo, J, Elorza, A, Sanz, P, Casanova, M J, Ferreiro-Iglesias, R, Pérez-Galindo, P, Benítez, J M, Taxonera, C, García García, M J, Martín Arranz, E, Calafat, M, Martín-Cardona, A, Muñoz Núñez, F, Miquel-Cusachs, J O, Sáinz Arnau, E, Gisbert, J P

“…Abstract Background Crohn's disease (CD) is chronic inflammatory disease of the gastrointestinal tract. Tacrolimus (TCR) is a calcineurin inhibitor drug…”
Get full text

DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU by Rodriguez-Lago, I, Castro-Poceiro, J, Fernández-Clotet, A, Mesonero, F, López-Sanromán, A, López-García, A, Márquez, L, Clos-Parals, A, Cañete, F, Vicuña, M, Nantes, Ó, Merino, O, Matallana Royo, V, Gordillo, J, Elorza, A, Vicente, R, Casanova, M J, Ferreiro-Iglesias, R, Pérez-Galindo, P, Benítez, J M, Taxonera, C, García García, M J, Martín Arranz, E, Calafat, M, Martín-Cardona, A, Muñoz Núñez, F, Miquel-Cusachs, J O, Sáinz Arnau, E, Gisbert, J P

“…Abstract Background Ulcerative colitis (UC) is a chronic disorder of the gut. Tacrolimus (TCR) is a calcineurin inhibitor drug commonly used for prophylaxis of…”
Get full text

The most informative abstracts of research papers: suggestion of a model by dos Santos, I, Clos, A C

“…Considering proposals on research work writing which point out importance elements for dissemination of scientific findings, the authors have as aims testing a…”
Get full text

Styles of conflict management among nurses. Instrument validation by Francisco, M T, Clos, A C, dos Santos, I, Larrubia, E de O

“…The present study has as an object the modalities of conflict administration adopted by nurses in professional praxis. Considering the Management Grid Theory…”
Get full text

The most informative abstracts of research papers: suggestion of a model by dos Santos, I, Clos, A C

Get full text

Behavioural effects and regulation of PKCa and MAPK by huprine X in middle aged mice by Ratia, M, Gimenez-Llort, L, Camps, P, Munoz-Torrero, D, Clos, MA[ordfV, Badia, A

“…The behavioural effects of huprine X, a new anticholinesterasic inhibitor, as well as its effects on the regulation of protein kinase C (PKC), mitogen…”
Get full text